The investigators aim to explore if systematic follow-up of newer generation serum antiepileptic drugs levels can provide a tangible benefit in the care of people with epilepsy. "Systematic therapeutic drug monitoring" performed at each clinic consultation and automatically transmitted to the clinician will be compared with clinically required therapeutic drug monitoring ("rescue therapeutic drug monitoring", transmitted only in case of predefined inefficacy or tolerance problems, as defined in the combine endpoint below), to assess if systematic therapeutic drug monitoring can prevent a proportion of treatment failure or adverse events. In the "rescue therapeutic drug monitoring" arm, communication of levels results will only be provided if a study endpoint (treatment failure or side effect as discussed below) is reached. This design has been previously successfully used by our group in an oncological setting. A combined endpoint will be used accounting for both efficacy and adverse events; occurrence of any of those events will be considered as an endpoint: 2 seizures with impaired consciousness, status epilepticus (defined as any seizure lasting >5 minutes), need of an add-on antiepileptic drugs, need to discontinue the study drug (lack of efficacy or adverse reactions) or hospital admission.